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Key Points: 
Low volume, high throughput whole blood aggregometry will facilitate future mouse platelet 
function research. 
Application of this approach identifies ICAM-1 as a novel mediator of platelet-monocyte 
interaction through fibrinogen binding. 
 
Abstract 
Testing of platelet function is central to the cardiovascular phenotyping of genetically 
modified mice.  Traditional platelet function tests have been developed primarily for testing 
human samples and the volumes required make them highly unsuitable for the testing of 
mouse platelets.  This limits research in this area.  To address this problem we have 
developed a miniaturised whole blood aggregometry assay, based on a readily accessible 
96-well plate format coupled with quantification of single platelet depletion by flow cytometric 
analysis.  Using this approach we observed a concentration-dependent loss of single 
platelets in blood exposed to arachidonic acid, collagen, U46619 or protease activated 
receptor (PAR) 4 activating peptide.  This loss was sensitive to well established antiplatelet 
agents and genetic manipulation of platelet activation pathways.  Observations were more 
deeply analysed by flow cytometric imaging, confocal imaging, and measurement of platelet 
releasates.  Phenotypic analysis of the reactivity of platelets taken from mice lacking 
intercellular adhesion molecule (ICAM) 1 identified a marked decrease in fibrinogen-
dependent platelet monocyte interactions, especially under inflammatory conditions.  Such 
findings exemplify the value of screening platelet phenotypes of genetically modified mice 
and shed further light upon the roles and interactions of platelets in inflammation. 
 
Introduction 
Platelets are key mediators of haemostasis.  They have crucial roles in certain bleeding 
disorders and are the targets of anti-thrombotic therapies, notably aspirin and P2Y12 receptor 
blockers, such as clopidogrel1-3.  Numerous assays have been developed to investigate 
platelet responses with an understandable focus on analysing human clinical samples4,5.  
These assays require relatively large volumes of blood with the majority requiring a sample 
volume in excess of 200µl per test6. 
 
Mouse models are widely used in cardiovascular research, particularly for phenotyping of 
genetic modifications and testing novel therapeutic agents.  However, platelet function 
testing in mice remains difficult since a complete and terminal blood collection provides at 
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most 1ml of blood.  Further, commonly used strategies for extending the volume available 
such as dilution or platelet washing can introduce artefactual changes in platelet responses 
and thus does not permit study of platelet interactions with other blood cells and 
constituents.  As a result both the number and type of platelet tests that can be performed in 
samples from mice are severely limited, diminishing the experimental value of each mouse 
and making detailed study of mouse platelets impractical.  There is therefore a clear and 
pressing experimental demand for murine-focused and optimised functional assays. 
 
We have previously developed the ‘Optimul’ assay for measuring platelet aggregation in low 
volumes (40µl) of platelet-rich plasma7,8, and have very recently reported its utility in the 
testing of platelet function patients with bleeding disorders9.  However, the ‘Optimul’ system 
relies on optical measurement of sample turbidity to assess platelet aggregation, making it 
unsuitable for analysis of platelet function in whole blood.  Several studies have 
demonstrated platelet counting to be a viable alternative method for monitoring platelet 
aggregation, since single platelets are ‘consumed’ into larger aggregates upon activation10-
12
.  Similarly it has also previously been demonstrated that flow cytometry can be used to 
determine platelet counts in ~5µl of blood by reference to known amounts of enumeration 
beads13.  With flow cytometry now widely available, such an approach provides an attractive 
and viable solution for determining platelet aggregation in low-volumes of blood.  
 
By combining ex vivo stimulation of platelets in small volumes of whole blood in 96-well 
plates with flow cytometric counting of single platelets, we have developed a novel and 
accessible experimental approach for ex vivo platelet function testing in mice.  Here, we 
confirm the sensitivity and specificity of this assay by demonstrating its ability to detect 
pharmacological and genetic interruption of well-established and clinically relevant platelet 
activation pathways involving the P2Y12 receptor and cyclo-oxygenase (COX)-1.  
 
Moreover, given that platelet reactivity is studied in a whole blood setting, we applied this 
novel assay to examine the platelet response phenotype in whole blood of mice lacking 
adhesion receptors.  Crucially we identified intracellular adhesion molecule (ICAM) 1, 
through fibrinogen binding, as a previously unreported mediator of platelet-monocyte 
interactions. 
 
Materials and Methods 
Mouse strains  
COX-1 knockout (KO), and ICAM-1 mice were previously generated on a C57Bl/6J 
background and identified by genomic PCR as described14,15.  C57Bl/6 wild type (WT) mice 
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were purchased from Charles River UK. All mice were aged between 8-12 weeks (20-25g) 
and housed for a minimum of 7 days before commencement of experiments.  They were 
housed on a 12-hour light-dark cycle, at a temperature of 22-24°C with access to water and 
food ad libitum.  Animal procedures were conducted in accordance with Home Office 
legislation under “The Animals (Scientific Procedures) Act 1986” and were subject to local 
approval from Queen Mary University of London and Imperial College London Ethical 
Review Panels. 
 
Collection of blood and preparation of platelet rich plasma 
Blood was collected from the inferior vena cava into either lepirudin (RefludanTM, 25 μg/ml; 
Celgene, Windsor, UK), sodium citrate (0.32%; Sigma, Poole, UK) or heparin (10U/ml; 
Wockhardt, Wrexham, UK) from mice anesthetized with ketamine (Narketan®, 100 mg/kg; 
Vetoquinol, UK) and xylazine (Rompun®, 10 mg/kg; Bayer, Kiel, Germany).  Platelet rich 
plasma (PRP) was isolated as previously published by Woulfe et al16.  Briefly, whole blood 
was diluted 1:1 with HEPES-tyrodes buffer (37 mM NaCl, 20 mM HEPES, 5.6 mM glucose, 1 
g/l BSA, 1 mM MgCl2, 2.7 mM KCl, 3.3 mM NaH2PO4) before centrifugation (100 g, 8mins, 
RT).   
 
Platelet or whole blood stimulation  
Half-area 96-well microtitre plates (Greiner Bio-One, Stonehouse, UK) were pre-coated with 
hydrogenated gelatine (0.75% w/v; Sigma, UK) in PBS to block non-specific activation of 
blood.  4μl of vehicle or agonist solution was then added to each well: arachidonic acid (AA; 
0.05–0.5mM; Sigma, Poole, UK), Horm collagen (0.1–10μg/ml; Nycomed, Linz, Austria), the 
PAR-4 activating peptide AYPGKF amide (PAR4-amide, 50–100mM; Bachem, Bubendorf, 
Switzerland), and the stable thromboxane (Tx) A2 mimetic U46619 (0.1–10μM; Cayman 
Chemical Company, Ann Arbor, USA).  These platelet agonists are most widely used in 
in vitro platelet testing17. 
 
To each well, 35μl of PRP or whole blood was added and the plate was then placed onto a 
heated plate shaker (Bioshake IQ, Q Instruments, Jena, Germany) at 37°C for 5 mins mixing 
at 1200rpm.  Where appropriate, light transmission of each well was determined using a 96-
well plate reader (SunriseTM, Tecan, Mannedorf, Switzerland) at 595nm.  Following mixing, 
5μl was removed from each well and diluted 1:10 into an acid citrate dextrose solution (5mM 
glucose, 6.8 mM trisodium citrate, 3.8 mM citric acid).  In some experiments, blood was pre-
treated with the P2Y12 receptor blocker prasugrel-active metabolite (PAM; 30μM) or its 
vehicle (0.5% DMSO) for 30 mins at 37 °C.  Alternatively, blood was pre-incubated with 
prostacyclin (PGI2, Epoprostenol, 2μg/ml; Tocris bioscience, Abingdon, UK) for 1 min 
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immediately before agonist stimulation.  In ICAM-1 KO experiments whole blood was pre-
incubated with murine TNF-α (20ng/ml; Life Technologies, Paisley, UK), eptifibatide 
(10μg/ml) or Fibrinogen γ-Chain 117-133 (20μM; Bachem, Switzerland, for both). 
 
Flow cytometry 
Individual platelet counts of each well were determined according to Alugupalli et al13.  
Briefly, platelets were labelled with FITC or APC conjugated anti-CD41 (clone 
eBioMWReg30) or anti-CD42d-PE (clone 1C2) monoclonal antibodies (eBioscience, 
Hatfield, UK) for 30 mins.  Samples were then diluted 1:50 in phosphate buffered saline 
containing 0.1% formalin (Sigma, UK), 0.1% dextrose and 0.2% bovine serum albumin 
(BSA) before addition of 104 CountBright™ absolute counting beads (Life Technologies).  
Labelled, diluted blood was then analysed using a FACSCalibur flow cytometer (BD 
Biosciences, Oxford, UK).   
For more in-depth analysis of cell-interactions an ImageStreamX MarkII imaging flow 
cytometer was used, as this combines the quantitative power of flow cytometry with high 
content image analysis by acquiring up to twelve images simultaneously of each cell or 
object including brightfield, scatter, and multiple fluorescent images.  Images were analysed 
using IDEAS software (Amnis, Seattle, WA).  To prepare samples, whole blood samples 
were stained with anti-CD41-FITC (platelets), anti-CD45-PE (leukocytes, clone 30F11), and 
anti-Ter119-APC (erythrocytes clone Ter-119, all Miltenyi Biotec, Bisley, UK) then fixed and 
diluted in a formalin/PBS solution containing dextrose and BSA.  To study platelet-monocyte 
interactions, whole blood samples were fixed and erythrocytes removed using Lyse/Fix (BD 
Bioscience) before staining with anti-CD42d-PE, anti-mouseLy6C-APC (clone HK1.4, 
eBioscience) for monocytes or anti-mouseCD54 (clone YN1/1.7.4) for ICAM-1.   
 
Confocal microscopy 
Blood was stimulated as described above.  Platelets were stained using a rat anti-mouse 
CD42c-DyLight488 antibody (Emfret, Eibstadt, Germany).  Cells were fixed and red blood 
cells were lysed using commercially available 1-step Fix/Lyse (eBioscience).  Neutrophils 
were then stained for intracellular MRP-14 (S100A9), using a goat anti-MRP-14 polyclonal 
antibody conjugated to Alexa Fluor 555 (R&D systems, Abingdon, UK).  Immunofluorescent-
labelled cells were imaged using a Zeiss LSM 5 PASCAL confocal laser-scanning 
microscope incorporating an x63 oil-dipping objective (numerical aperture 1.4).  Z-stack 
images were acquired using the multiple track scanning mode at a resolution of 1,024 × 
1,024 pixels in the x × y plane and 0.4µm steps in z direction.  Resulting 3D confocal images 
were then analysed using the image processing software IMARIS (Bitplane, Zurich, 
Switzerland). 
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Analysis of thromboxane A2 production 
Following stimulation of whole blood samples, COX activity was halted by the addition of 1 
mM diclofenac (Sigma), the samples were centrifuged at 1300 g for 10 min at 5°C.  Plasma 
supernatants were then removed and stored at -80oC.  Thromboxane (TX) B2 levels in the 
supernatant, as a measure of TXA2 formation, were determined by selective ELISA (Cayman 
Chemical, Ann Arbour, USA). 
 
Statistics and data analysis 
Data presented as mean ±SEM, and analysed using FlowJo v7.4 (Treestar, Ashland, USA) 
and Prism 5.01 (GraphPad software, USA).  For analysis, the “single platelet” population 
was gated based on forward scatter and anti-platelet immunoreactivity (fluorescence 
intensity).  Statistical significance was determined by two-way ANOVA with Dunnett’s post-
hoc test unless otherwise stated, and data sets considered different if p<0.05.  Each n value 
represents a data point from a separate animal. 
 
Results and discussion 
Detection of single platelets and agonist-induced platelet aggregation 
In order to establish a viable platelet aggregation assay based on the platelet counting 
technique it was first necessary to demonstrate the robust detection of single platelets in 
whole blood and determine their fate upon stimulation with platelet activating substances.  
By flow cytometry analysis, a population of sub-cellular sized particles immunoreactive to the 
platelet marker CD41 (GPIIb) was clearly detected in unstimulated blood13 (Figure 2a).  
Mixing of blood in a 96 well plate as described above, had no effect on this ‘single platelet’ 
population (Figure 2b) consistent with data from traditional ex vivo aggregation assays 
where mixing alone does not cause platelet activation.  Conversely, in the presence of 
classical platelet activating agonists such as collagen, the thrombin receptor (PAR4)-
activating peptide, PAR4-amide, or the TxA2-mimetic, U46619 there were marked depletions 
of the single platelet population (Figure 2c).  Such losses of single platelets have been 
previously reported as measures of platelet aggregation10-12.  By using enumeration beads to 
quantify the single platelet count per volume it was possible to accurately quantify depletion 
and make comparisons between samples.  Using this approach, we recorded concentration-
dependent losses of the single platelet population (Figure 2d – 2f).  In response to 10μg/ml 
collagen stimulation 13±4% of single platelets remained, i.e. a maximal reduction of 87±4% 
with a co-efficient of variance (CV) of 16.1% (n=11). PAR4-amide stimulation led to a 
maximal loss of 79±5% (7.8% CV, n=9), and U46619 of 89±3% (7.4% CV, n=10). These 
agonists produced single platelet loss at concentrations that were similar to those previously 
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found to cause aggregation of mouse platelets in traditional assays15,16. To validate our 
observations we used a separate and distinct platelet marker, CD42d (GPV) and observed 
near identical platelet counts when we analysed separately for each marker over a range of 
activation conditions (r2=0.998 by linear regression analysis; suppl. Figure 1).  
 
We next went on to confirm if single platelet loss in stimulated whole blood is an active, 
inhibitable process.  To do this, we pre-incubated blood with the powerful platelet inhibitor 
PGI2, and found significant reductions in the single platelet depletion induced by maximal 
tested concentrations of all agonists: collagen, 87±4% of single platelet loss vs. 47±10 with 
PGI2; PAR4-amide, 79±5% vs. 25±9%; and U46619, 89±2% vs. 26±7% (Figures 2d – 2f).  
These data demonstrate that the observed agonist-stimulated depletion of the single platelet 
population in this assay is an active process and not a result of chemical disruption or 
agglutination.  It also demonstrates that the assay can detect the effect of inhibitory 
substances acting through platelet intracellular signalling pathways.  Importantly, because 
each test condition requires only 35μl of blood, this panel of 3 agonists, each at 4 
concentrations was testable using ~0.5ml of blood, half the total accessible blood volume of 
a mouse.  Indeed, since a large sample volume remains after platelet counting for additional 
analyses, we also measured the formations of TxA2 in response to collagen and separately 
to AA by immunoassay (suppl. Figure 2a, 2b), and found a clear association between the 
potencies of agonists as stimulants of TxA2 formation and single platelet loss. 
 
To explore the cause of agonist-induced loss of single platelets we examined unstimulated 
and collagen-stimulated mouse blood by confocal microscopy and imaging flow cytometry 
after immunofluorescent staining of platelets, leukocytes and erythrocytes.  Vehicle-treated 
blood showed an abundance of single platelets and neutrophils with little interaction between 
cell types (Figure 2gi, 2gii).  After stimulation with collagen, however, blood showed a 
depletion of single platelets together with the appearance of multiple large groups 
comprising platelet-platelet and platelet-leukocyte aggregates (Figures 2hi, 2hii) consistent 
with the associated single platelet depletion. 
 
Having established a platelet-counting based activation assay in whole blood, we explored 
the applicability of the approach to studies in platelet-rich plasma.  This preparation, 
although less physiological, can be valuable for platelet-focused studies in which other blood 
cells/components may confound the interpretation of results.  Using the same assay 
conditions and measurement technique, mouse platelet-rich plasma behaved similarly to 
whole blood, showing concentration-dependent single platelet depletion in response to 
collagen, U46619 and PAR4-amide (suppl. Figure S3).  The potency of these agonist and 
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sensitivity of detection as determined by platelet counting was similar to that recorded when 
aggregation was measured by the more conventional light transmission approach8 (suppl. 
Figure S3).  Finally, to confirm the suitability of this mouse whole blood assay to blood 
collected into different, more conventional anti-coagulants, we measured AA-, collagen-, 
PAR4-amide- and U46619-induced single platelet depletion responses in blood collected 
into sodium citrate or heparin.  In both cases, we observed similar agonist-induced single 
platelet depletion responses as those described above for lepirudin anti-coagulated blood 
(suppl. Figure S4). 
 
Detection of the anti-platelet effect of P2Y12 receptor blockade and COX1-deficiency 
After defining this assay, we wanted to consider its sensitivity to loss of known platelet 
signalling pathways.  We examined the COX-1/TxA2 and ADP-P2Y12 receptor pathways 
since in contrast to PGI2 their interruption produces a more modest and selective alteration 
in platelet responsiveness, and both directly translate to existing therapeutics in clinical use.  
 
Prasugrel, like clopidogrel, is a blocker of the ADP-receptor P2Y1218-20.  It is well established 
that P2Y12 blockade has significant effects upon platelet responsiveness to collagen, 
U46619 and PAR4 agonists consistent with its anti-thrombotic effect in man21-23.  We found 
that the P2Y12 receptor blocker prasugrel active metabolite (PAM, 3μM) markedly prevented 
agonist-induced single platelet loss, as compared to vehicle (0.5% DMSO).  This inhibition 
persisted even at the highest concentrations tested of collagen (72±10% vs. 58±11%), 
PAR4-amide (80±4% vs. 11±6%), and U46619 (50±15% vs. 1±1%) (Figure 3a – 3c).  
 
COX-1, the therapeutic target of aspirin, converts AA into prostaglandin H2, a catalytic step 
required for the generation of TxA2 by activated platelets.  Using our assay we observed that 
platelets in blood from COX-1-deficient mice demonstrated a complete absence of the 
response to 0.1mM AA, whilst wild-type (WT) mice demonstrated a strong response (WT, 
71±7% vs. KO, 1±2%).  Platelet responses to collagen were also blunted in blood from COX-
1-deficient mice, even at maximal concentrations (WT, 71±5% vs. KO, 34±13%; Figure 4a).  
In contrast, COX-1-deficiency had little effect on responses to PAR4-amide or U46619 
(Figures 4b & 4c).  Again, this is consistent with the established role of COX-1-derived TxA2 
in the response to collagen but not to thrombin receptor stimulation by PAR4-amide or 
exogenous thromboxane (U46619)24-27. 
 
The ability of the assay described here to detect reproducibly the anti-thrombotic effects of 
P2Y12 receptor blockade and COX-1 gene deletion demonstrates its suitability for detecting 
specific defects in platelet signalling.  Data from COX-1-deficient mice are particularly 
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relevant since screening and initial phenotyping of platelet function in genetically modified 
mice could be an important application of this assay.  This data also highlights the 
importance of testing a range of platelet responses in parallel since COX-1 deletion 
selectively modifies responses to AA and collagen without affecting those to PAR4-amide 
and U46619.  This is possible in the assay presented here because the blood volumes 
required for each test are very low, allowing study of multiple pathways in parallel to 
generate a broad response profile for each mouse tested. 
 
Altered platelet phenotypes in mice lacking intercellular adhesion molecule (ICAM)-1 
Having developed a robust mouse platelet function assay we next wanted to apply the 
technique to a novel biological question.  Since a particular benefit of this assay is the ability 
to monitor platelet-leukocyte interactions in activated whole blood, we sought to screen mice 
deficient in specific leukocyte adhesion molecules to determine whether these adhesion 
molecules contribute to platelet-leukocyte and platelet-platelet interactions.  Through this 
approach we found that deletion of ICAM-1 attenuates single platelet loss (wild-type: 
39±14% vs. ICAM-1 KO: 14±8%; Figure 5a) in response to sub-maximal concentration of 
U46619.  However when platelet function was studied in PRP no such differences were 
observed (suppl. Figure S5), demonstrating that the effect of ICAM-1 is dependent on blood 
cells/constituents other than platelets.  ICAM-1, expressed on lymphocytes, neutrophils, 
monocytes and endothelial cells but not on platelets is known to play a key role in leukocyte 
transmigration through the endothelial cell layer28,29.  Given we have established that 
platelet-leukocyte interactions play a role in the observed single platelet depletion and that 
we only observed an effect of ICAM-1 deletion on the response to the TXA2 mimetic 
U46619, which unlike collagen and PAR4-amide, activates leukocytes as well as platelets, 
we reasoned ICAM-1 may be a mediator of platelet-monocyte binding.  To confirm this we 
examined U46619-stimulated samples by flow cytometric imaging (Figure 5b). Upon 
quantification significantly less platelet-monocyte interactions were present in ICAM-1 KO 
mice compared to WT (WT: 41±1%; ICAM-1 KO: 27±2%; Figure 5c) suggesting that ICAM-1 
may particularly drive platelet-monocyte interactions.  
 
Basal monocyte ICAM-1 expression is relatively low but is greatly increased during 
inflammation30.  We therefore sought to stimulate monocyte ICAM-1 induction by incubating 
whole blood with murine TNF-α, which led to a time-dependent increase in monocyte ICAM-
1 immunoreactivity (suppl. Figure S6). mTNF-α treatment also increased ‘basal’ platelet-
monocyte interactions, in both WT and ICAM-1 KO mouse blood.  In blood primed with 
mTNF-α, U46619-induced platelet-monocyte adhesion in WT mouse blood was significantly 
increased from 41±1% to 58±3%.  However, in blood from ICAM-1 KO mice, the ability of 
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mTNF-α to potentiate U46619-induced platelet-monocyte interactions was abolished (27±2% 
no mTNF-α vs 32±6% with mTNF-α; Figure 5c & 5d), indicating that the potentiation of 
U46619-induced platelet-monocyte association produced by mTNF-α is ICAM-1-dependent. 
 
Lastly, we wanted to examine the mechanism of interaction between monocyte ICAM-1 and 
platelets. ICAM-1 mediates leukocyte-leukocyte interactions primarily by binding to 
lymphocyte function-associated antigen (LFA)-1.  Although LFA-1 has been described on the 
mouse platelet surface it is present only at a low level31.  ICAM-1 can also directly bind 
fibrinogen to mediate indirect leukocyte adhesion32.  Given that activated platelets avidly 
bind fibrinogen by the glycoprotein (GP)IIb/IIIa complex we hypothesised this may also serve 
as a mechanism for ICAM-1-mediated platelet-leukocyte interactions.  To test this we 
repeated previous experiments using U46619 and murine TNF-α with the addition of 
eptifibatide, a competitive inhibitor of fibrinogen binding to the platelet2.  Under these 
conditions we found that the observed increases in platelet-monocyte interactions were 
reversed in WT blood (23±2%) to the levels observed in blood from ICAM-1 KO mice 
(27±2%; Figure 5c & 5d).  Since eptifibitide inhibits only platelet fibrinogen binding, we also 
performed experiments in the presence of an excess of the fibrinogen γ-117–133 peptide 
sequence.  This mimics the ICAM-1-binding sequence within fibrinogen33,34 and thus actively 
compete with native fibrinogen35 for monocyte ICAM-1 binding.  We observed that in the 
presence of this excess peptide, platelet-monocyte interactions induced by U44619 and 
TNF-α were significantly decreased from 59±3% to 40±5% in WT mice, while there was no 
change in interactions observed in ICAM-1 KO mice (32±6% to 28±3%, Figure 5c).  This 
supports the conclusion that fibrinogen acts as a ligand for ICAM-1-dependent platelet-
monocyte binding. 
 
These data identify a novel role of ICAM-1 in mediating platelet-monocyte interaction, 
particularly under conditions of inflammation (i.e. as modelled by addition of TNF-α).  This 
raises questions as to whether ICAM-1 may also mediate platelet binding to other cell types 
such as neutrophils and endothelial cells and whether this mechanism may contribute to the 
role of platelets in vascular inflammation36.  For example, platelet-leukocyte aggregates have 
been identified as key contributors to the pathogenesis of atherosclerosis37, sepsis38 and 
more recently, venous thrombosis39.   
 
Summary and conclusions 
Here we have described and validated a low volume, 96-well plate based whole blood 
mouse platelet aggregation assay that has significant advantages over currently established 
assays.  Firstly, by requiring only 35μl of blood per replicate it permits a higher number of 
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simultaneous tests to be conducted without the need for excessive platelet handling that can 
introduce artefacts.  Secondly, this assay can readily be used for particular platelet-focused 
studies.  Consequently, a detailed platelet phenotype informed by use of activators and 
inhibitors that signal through multiple intracellular signalling pathways can be revealed with 
the minimal use of animals.  This not only provides a thorough understanding of platelet 
thrombotic pathways but may also be of value in identifying potential signalling defects that 
may reflect physiology in other cell types that are less accessible for testing.  Here, our 
application of this assay to phenotype responses from ICAM-1 deficient mice and 
subsequent identification of ICAM-1, through binding fibrinogen, as being a novel mediator of 
platelet-monocyte interaction is demonstration of its utility.  Moreover, this approach may be 
of particular use in prospective phenotyping of novel genetically modified mice such as those 
generated by knock-out mouse consortia 40,41.  In conclusion, the refined, robust and readily 
accessible assay we present here addresses an important scientific need by improving 
current experimental methodology for murine platelet testing. 
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Figure Legends 
  
Figure 1: Schematic diagram of methodology.  Whole blood is removed from the vena 
cava of an anaesthetised mouse, aliquoted into an agonist containing 96-well plate, before 
mixing at 37°C for 5 mins.  Subsequently, blood is sampled from each well, diluted and 
stained using specific anti-platelet antibodies.  Quantitative beads are then added before 
single platelet counts are acquired. 
 
Figure 2: Concentration-dependent loss of single platelets following agonist 
stimulation due to formation of platelet-platelet and platelet-leukocyte aggregates. 
Representative dot plots of platelet populations and quantitative gating, as identified by anti-
CD41 APC antibody staining in, A) unmixed blood and B) vehicle mixed samples remains 
stable.  Platelet population was depleted in C) agonist (collagen 1μg/ml) mixed samples.  
Platelet loss occurred in a concentration-dependent manner following treatment with 
increasing concentrations of the common agonists D) collagen, E) PAR4-amide AYPGKF, 
and F) U46619.  Loss was significantly reduced by inclusion of prostacyclin (Epoprostenol, 
2μg/ml). Analysis of Gi) vehicle-stimulated and Hi) collagen-stimulated whole blood acquired 
using an ImagestreamX MarkII incorporating a x 60 objective lens, scale bars equal to 7μm 
identified platelet-platelet and platelet-leukocyte aggregates. Platelets identified by anti-
CD41 (green), leukocytes by anti-CD45 (yellow) and erythrocytes by anti-Ter119 (red).  
Confocal imaging of Gii) vehicle-treated and Hii) collagen-stimulated samples, with 
subsequent erythrocyte-lysis, confirmed respective absence and presence of stimulated 
platelet (CD42c, green)-platelet and platelet-neutrophil (MRP-14, red) aggregates.  Images 
were acquired in 3D by confocal microscopy using a Zeiss LSM 5 PASCAL confocal laser-
scanning microscope incorporating a x 63 oil-dipping objective lens (numerical aperture 1.4) 
and the image acquisition software IMARIS.  Scale bars equal to 20μm. Data reported as 
mean ± SEM (n=3-11), *p<0.05 by paired t-test. 
 
Figure 3: Sensitivity of assay to P2Y12 inhibition.  Pre-treatment of whole blood with the 
P2Y12 receptor blocker prasugrel active metabolite (PAM, 3μM) inhibited the platelet 
response to A) 1μg/ml collagen, B) PAR4-AP, or C) U46619.  Data reported as mean ± SEM 
(n=6). *p<0.05 by two way ANOVA versus vehicle (0.5% DMSO). 
 
Figure 4: Phenotype of COX-1 knock-out mice.  Responses of platelets in blood from 
COX-1 knockout mice, compared to wild type mice, were significantly inhibited for A) 
collagen, and for lower concentrations of B) PAR4 amide or C) U46619.  Data reported as 
mean ± SEM (n=6). *p<0.05 by two way ANOVA. 
 
Figure 5: Phenotypic analysis of ICAM-1 knock-out mice and role in platelet-monocyte 
interaction. Platelet reactivity in blood from ICAM-1 knockout mice, compared to wild type 
mice, were no different following A) collagen or PAR4 amide stimulation but significantly 
inhibited in response to 0.3μM U46619 (n=6 for all). B) Flow cytometric imaging (x60 
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objective) of samples stimulated by U46619 (0.3μM) revealed a potential difference in 
platelet (green) monocyte (red) interactions. Scale bars equal to 7μm. C) Quantitation of 
these interactions identified significantly more platelet-monocyte interactions upon U46619 
stimulation in wild-type compared to ICAM-1 KO mice. In wild-type mice this interaction was 
exaggerated when blood was pre-stimulated with mTNF-α but reversed when performed in 
the additional presence of eptifibatide, or the fibrinogen peptide γ-117–133.  The level of 
interaction in ICAM-1 KO mice remained constant through all conditions (n=3 for all). D) 
Corresponding representative histograms of platelet (CD42d-PE) binding of the Ly6C 
(monocyte) positive population in WT (left) and KO (right) mice in absence (red) and 
presence (blue) of eptifibatide. Data presented as mean ± SEM, *p<0.05 by two-way 
ANOVA.  
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